RNXT · RenovoRx, Inc.

$1.20 -0.20 (-14.29%)

Market Cap

$63.18M

45.13M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Shaun R. Bagai	Chief Executive Officer	$583,441	$227,834	—	$418,038	—	$3,004	$1,232,317
Shaun Bagai	CEO	$583,441	$227,834	—	$418,038	—	$3,004	$1,232,317
Ramtin Agah	Chief Medical Officer	—	—	—	$259,538	—	$432,708	$692,246
Ronald Kocak	—	$346,097	$85,733	—	$169,666	—	$15,200	$616,696
Ronald B. Kocak	Vice President, Controller and Principal Accounting Officer	$346,097	$85,733	—	$169,666	—	$15,200	$616,696

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Shaun Bagai	CEO	$520,000	$400,457	—	$259,222	—	$46,371	$1,226,050
Shaun R. Bagai	Chief Executive Officer	$520,000	$400,457	—	$259,222	—	$46,371	$1,226,050
Leesa Gentry	Chief Clinical Officer	$339,386	$178,227	—	$357,557	—	$14,981	$890,151
Ramtin Agah	Chief Medical Officer	—	$169,957	—	$129,612	—	$303,450	$603,019

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Shaun Bagai	CEO	$520,000	$69,376	—	$349,739	—	—	$936,779
Shaun R. Bagai	Chief Executive Officer	$520,000	$69,376	—	$349,739	—	—	$936,779
Angela Gill Nelms	Former Chief Operating Officer	$412,000	$34,980	—	$87,435	—	$14,397	$547,634
Ramtin Agah	Chief Medical Officer	—	$29,444	—	$174,870	—	$303,450	$506,772
Leesa Gentry	Chief Clinical Officer	—	—	—	—	—	—	—

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Shaun Bagai	CEO	$495,000	—	—	$123,324	$222,750	—	$841,074
Shaun R. Bagai	Chief Executive Officer	$495,000	—	—	$123,324	$222,750	—	$841,074
Angela Gill Nelms	Former Chief Operating Officer	$115,152	—	—	$535,736	$35,901	$20,500	$707,288
Ramtin Agah	Chief Medical Officer	—	—	—	$54,621	$91,035	$289,000	$434,655

Executive changes

Person	Role	Change	Effective	Filed
Ramtin Agah, M.D.	Executive Chairman	Appointed	2026-02-27	2026-03-27
Mark Voll	Chief Financial Officer	Appointed	2026-02-04	2026-02-06
Ronald B. Kocak	Principal Accounting Officer	Resigned	2026-02-03	2026-02-06
Una S. Ryan, O.B.E., Ph.D., D.Sc.	director	Appointed	2024-06-06	2024-06-07
Laurence J. Marton, M.D.	director	Appointed	2024-06-06	2024-06-07
Robert J. Spiegel, M.D., FACP	director	Appointed	2024-06-06	2024-06-07
Ramtin Agah, M.D., FACP	director	Appointed	2024-06-06	2024-06-07
Kirsten Angela Macfarlane	director	Appointed	2024-06-06	2024-06-07
Shaun R. Bagai	director	Appointed	2024-06-06	2024-06-07
Leesa Gentry	Chief Clinical Officer	Appointed	2024-03-01	2024-03-14
Leesa Gentry	Chief Clinical Officer	Appointed	2024-03-01	2024-02-23
Angela Gill Nelms	Chief Operating Officer	Resigned	2024-03-01	2024-02-23
Ronald B. Kocak	Vice President, Controller and Principal Accounting Officer	Appointed	2024-02-08	2024-02-09
James Ahlers	Chief Financial Officer	Resigned	2024-02-05	2024-02-09
Robert Spiegel, M.D.	independent director	Appointed	2023-04-25	2023-04-27
Angela Gill Nelms	Chief Operating Officer	Appointed	2022-09-19	2022-09-19
James Ahlers	Secretary and Treasurer	Appointed	2022-07-15	2022-07-19
James Ahlers	Chief Financial Officer	Appointed	2022-07-15	2022-07-19
Christopher J. Lehman	Chief Financial Officer	Resigned	2022-07-15	2022-07-19

Key facts CIK 1574094 CUSIP 75989R107 13F (30d) 27 filings 27 filers Visit website Investor relations